The short answer: independent pharmacies sell at 2.25 to 2.97× SDE or 2.99 to 4.18× EBITDA, but only 0.21 to 0.34× revenue, the lowest revenue multiple of any vertical on this site, because insurers and pharmacy benefit managers set reimbursement and margins run thin. The asset you are buying is the script file: the prescription base that refills on schedule. The risk you are underwriting is everything between the script and the payment. In dollars: roughly $315,000 for a smaller $1.5M-revenue store to $1.7M for a $5M-revenue store, plus counted inventory at closing.
Why the revenue multiple is so low, and why buyers come anyway
A pharmacy's top line is large and its pricing power is small: most revenue flows through third-party reimbursement contracts whose rates the pharmacy does not control. That is why a dollar of pharmacy revenue is worth a fraction of a dollar of, say, agency revenue. What attracts buyers regardless is the refill engine: prescriptions recur on a schedule, patient files transfer in a sale, and a pharmacy with a stable file and decent contracts produces dependable cash flow that lenders understand. Front-of-store retail and clinical services (immunizations, compounding where permitted) are the margin layers on top.
The economics also explain the seller. Independent owners face chain and mail-order pressure on exactly the reimbursement contracts that set their margins, and many are pharmacists nearing retirement with no family successor, which keeps a steady supply of stable, decades-old files coming to market. For a buyer who understands the payer layer, that combination, durable demand plus motivated sellers, is the opportunity the low revenue multiple is quietly pricing in.
What pharmacies sell for
| Method | Typical figure | Notes |
|---|---|---|
| SDE multiple | 2.25–2.97× | The owner-operator yardstick |
| EBITDA multiple | 2.99–4.18× | How larger buyers price |
| Revenue multiple | 0.21–0.34× | Thin-margin reality: payers set the prices |
Within the range, the script file's quality decides the price: script count and trend, refill mix, how many prescribers feed the file, and the payer mix behind it. The valuation mechanics are the same as any deal, covered in our valuation guide; what changes is where the risk sits.
Worked through: a pharmacy filling steadily with $3,000,000 of annual revenue prices at just $630,000 to $1.02M on the revenue multiple (0.21–0.34×). If it nets $280,000 of SDE, the earnings method (2.25–2.97×) says $630,000 to $832,000, and the tight agreement between the two methods is typical here: the market has priced pharmacy margins for a long time. Add the counted inventory on top, usually financed or paid separately at closing, and you have the real check size.
| Business size | Implied price range | Note |
|---|---|---|
| Smaller store, $1.5M revenue | $315,000–$510,000 | Plus counted inventory at closing |
| Typical independent, $3M revenue | $630,000–$1.02M | The worked example above |
| Larger store, $5M revenue | $1.05M–$1.7M | Payer-contract quality dominates at this size |
Illustrative sizes priced with the sourced revenue-multiple range; inventory is always additional.
Where inside the band a specific pharmacy lands:
| Pushes the price up | Pulls it down |
|---|---|
| Growing script count across many prescribers | One or two prescribers feeding the file |
| Favorable, transferable reimbursement contracts | Reimbursement rates eroding year over year |
| A 65+ population in the trade area | Change-of-ownership re-credentialing risk |
| Tight inventory control and stock management | Stale or unmanaged inventory |
| Clinical services layered on (immunizations, compounding where permitted) | Pure dispensing with no margin layers |
The diligence that makes or breaks a pharmacy deal
| What to verify | The question it answers | Where it shows up |
|---|---|---|
| Script count and trend | Is the file growing, stable, or eroding? | Dispensing-system reports by month |
| Reimbursement contracts | What do the payers actually pay, and do the contracts survive a sale? | Each payer agreement; assignment and re-credentialing terms |
| Prescriber concentration | Does one retiring physician feed a third of the file? | Scripts by prescriber |
| Wholesaler agreement | What does inventory really cost, and is the deal transferable? | The primary wholesale contract |
| Inventory | What are you actually buying at closing? | A counted, dated inventory, priced separately |
The transfer that decides pharmacy deals
Payer re-credentialing. A change of ownership can require re-enrollment with payers, and gaps in credentialing interrupt the reimbursements that are most of the revenue. Map every contract's change-of-ownership process before you set a closing date.
Licensing: a pharmacist must be in charge
Pharmacy is among the most regulated purchases on this site: state pharmacy-board permits, a pharmacist-in-charge requirement in every state, DEA registration for controlled substances, and ownership rules that vary by state (a few restrict who may own; most regulate operation rather than ownership). The buy-side sequence, board change-of-ownership filings included, belongs to your attorney from day one, per what an M&A attorney does. Verify your state's rules with the board of pharmacy before the LOI.
How a typical pharmacy purchase is financed
| Source | Amount | % of price |
|---|---|---|
| SBA 7(a) loan | $720,000 | 90% |
| Equity injection (total) | $80,000 | 10% |
| of which: standby seller note can cover | up to $40,000 | up to 5% |
| of which: your cash portion | as low as ~$40,000 | ~5% |
Inventory is usually priced separately at closing on a physical count. The stack logic is in the acquisition financing guide; test coverage in the DSCR calculator.
Check a pharmacy's debt coverage
Where to find pharmacies for sale
| Channel | What you find there | How to work it |
|---|---|---|
| Pharmacy-specialist brokers | Most independent-pharmacy listings | Brief them on your state and size |
| Marketplaces | Some inventory | The marketplace comparison |
| Direct outreach | Independent owners facing chain pressure; wholesaler reps know who is selling | The off-market playbook |
Evaluating a pharmacy's script file?
The free training covers how members verify recurring revenue and structure regulated acquisitions.
Every claim checkable: member closings, self-reported and published unedited.
Frequently asked questions
Independent pharmacies sell at 2.25 to 2.97 times SDE or 2.99 to 4.18 times EBITDA, but only 0.21 to 0.34 times revenue, because payers set reimbursement and margins run thin. Inventory is typically priced separately at closing.
Because most revenue flows through third-party reimbursement contracts whose rates the pharmacy does not control. High revenue with payer-set pricing means a dollar of pharmacy revenue carries far less profit than a dollar of most other businesses' revenue.
Every state requires a pharmacist-in-charge to operate, and a few states restrict who may own a pharmacy. In most states a non-pharmacist can own while employing the pharmacist-in-charge. Verify your state's rule with the board of pharmacy before the LOI.
The script file first: script count and trend, refill mix, and prescriber concentration. Then the reimbursement contracts and their change-of-ownership terms, the wholesaler agreement, and a counted inventory. Payer re-credentialing gaps are the classic closing trap.
Yes. The standard structure is a 10% equity injection, about $80,000 on an $800,000 pharmacy, with up to half available as a standby seller note, and inventory financed or priced separately at closing.
Sources
Valuation multiples: Peak Business Valuation, Valuing a Pharmacy (average ranges published by a business appraiser, educational figures, not an appraisal of any specific agency). Ownership and pharmacist-in-charge rules vary by state; verify with the state board of pharmacy. Value drivers also per Peak, Value Drivers for a Pharmacy. SBA mechanics: our equity injection guide.
